Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1124.8000 -12.00 (-1.06%)
NSE Oct 14, 2025 15:31 PM
Volume: 1.0M
 

1124.80
-1.06%
Axis Direct
Aurobindo's (ARBP) Q3FY17 EBITDA (up 9% YoY) was 4% below our estimate. Gross/ EBITDA margin declined 180 bps/170 bps QoQ on increased price erosion of key oral solid products (gAbilify, gEntecavir) in US. While injectables grew over 80%, the growth could soften given withdrawal (post injunction) ..
Promoters pledged 0.42% of shares in last quarter. Total pledge stands at 17.50% of promoter holdings
More from Aurobindo Pharma Ltd.
Recommended